LifeMD® Announces Integration with LillyDirect Pharmacy Provider to Offer Patients Streamlined Access to Branded Dual GLP-1/GIP Zepbound
LifeMD (Nasdaq: LFMD) announced integration with LillyDirect's pharmacy provider Gifthealth to offer streamlined access to Zepbound® (tirzepatide), Lilly's FDA-approved prescription obesity treatment. The integration enables eligible patients to access single-dose vials at reduced self-pay prices with direct shipment.
Zepbound is the first dual GLP-1/GIP obesity medication approved by FDA. The integration complements LifeMD's insurance-sponsored pharmacy programs, where approval rates for branded GLP-1 therapies are increasing. The company's weight management program has reached approximately 75,000 active patient subscribers as of February 2025.
Through LillyDirect's self-pay pharmacy channel, Zepbound is available in 2.5 mg, 5 mg, 7.5 mg, and 10 mg dose vials. Lilly has reduced prices for 2.5 mg and 5 mg vials and launched new 7.5 mg and 10 mg vial options.
LifeMD (Nasdaq: LFMD) ha annunciato l'integrazione con il fornitore di farmacie LillyDirect, Gifthealth, per offrire un accesso semplificato a Zepbound® (tirzepatide), il trattamento per l'obesità approvato dalla FDA di Lilly. Questa integrazione consente ai pazienti idonei di accedere a fiale monodose a prezzi ridotti con spedizione diretta.
Zepbound è il primo farmaco per l'obesità a base di GLP-1/GIP approvato dalla FDA. L'integrazione si aggiunge ai programmi farmaceutici sponsorizzati da assicurazioni di LifeMD, dove i tassi di approvazione per le terapie GLP-1 di marca stanno aumentando. Il programma di gestione del peso dell'azienda ha raggiunto circa 75.000 abbonati attivi a febbraio 2025.
Attraverso il canale farmaceutico self-pay di LillyDirect, Zepbound è disponibile in fiale da 2.5 mg, 5 mg, 7.5 mg e 10 mg. Lilly ha ridotto i prezzi per le fiale da 2.5 mg e 5 mg e ha lanciato nuove opzioni da 7.5 mg e 10 mg.
LifeMD (Nasdaq: LFMD) anunció la integración con el proveedor de farmacias LillyDirect, Gifthealth, para ofrecer un acceso simplificado a Zepbound® (tirzepatide), el tratamiento para la obesidad aprobado por la FDA de Lilly. La integración permite a los pacientes elegibles acceder a frascos de dosis única a precios reducidos con envío directo.
Zepbound es el primer medicamento para la obesidad dual GLP-1/GIP aprobado por la FDA. La integración complementa los programas farmacéuticos patrocinados por seguros de LifeMD, donde las tasas de aprobación para las terapias GLP-1 de marca están aumentando. El programa de manejo de peso de la empresa ha alcanzado aproximadamente 75,000 suscriptores activos a febrero de 2025.
A través del canal farmacéutico de auto-pago de LillyDirect, Zepbound está disponible en frascos de 2.5 mg, 5 mg, 7.5 mg y 10 mg. Lilly ha reducido los precios de los frascos de 2.5 mg y 5 mg y ha lanzado nuevas opciones de frascos de 7.5 mg y 10 mg.
LifeMD (Nasdaq: LFMD)는 LillyDirect의 약국 제공업체 Gifthealth와 통합하여 Lilly의 FDA 승인 비만 치료제 Zepbound® (tirzepatide)에 대한 간소화된 접근을 제공한다고 발표했습니다. 이 통합은 적격 환자가 직접 배송으로 저렴한 자가 지불 가격으로 단일 용량 바이알에 접근할 수 있도록 합니다.
Zepbound는 FDA에 의해 승인된 최초의 이중 GLP-1/GIP 비만 약물입니다. 이 통합은 LifeMD의 보험 지원 약국 프로그램을 보완하며, 여기서 브랜드 GLP-1 요법의 승인 비율이 증가하고 있습니다. 회사의 체중 관리 프로그램은 2025년 2월 기준으로 약 75,000명의 활성 환자 구독자에 도달했습니다.
LillyDirect의 자가 지불 약국 채널을 통해 Zepbound는 2.5 mg, 5 mg, 7.5 mg 및 10 mg 용량의 바이알로 제공됩니다. Lilly는 2.5 mg 및 5 mg 바이알의 가격을 인하하고 새로운 7.5 mg 및 10 mg 바이알 옵션을 출시했습니다.
LifeMD (Nasdaq: LFMD) a annoncé son intégration avec le fournisseur de pharmacie LillyDirect, Gifthealth, pour offrir un accès simplifié à Zepbound® (tirzepatide), le traitement de l'obésité approuvé par la FDA de Lilly. Cette intégration permet aux patients éligibles d'accéder à des flacons à dose unique à des prix réduits avec expédition directe.
Zepbound est le premier médicament contre l'obésité à double GLP-1/GIP approuvé par la FDA. L'intégration complète les programmes pharmaceutiques sponsorisés par les assurances de LifeMD, où les taux d'approbation pour les thérapies GLP-1 de marque augmentent. Le programme de gestion du poids de l'entreprise a atteint environ 75 000 abonnés actifs en février 2025.
Grâce au canal de pharmacie de paiement direct de LillyDirect, Zepbound est disponible en flacons de 2,5 mg, 5 mg, 7,5 mg et 10 mg. Lilly a réduit les prix des flacons de 2,5 mg et 5 mg et a lancé de nouvelles options de flacons de 7,5 mg et 10 mg.
LifeMD (Nasdaq: LFMD) hat die Integration mit dem Apotheker LillyDirect, Gifthealth, angekündigt, um einen vereinfachten Zugang zu Zepbound® (tirzepatide), der von der FDA zugelassenen Verschreibung zur Behandlung von Fettleibigkeit von Lilly, zu bieten. Diese Integration ermöglicht es berechtigten Patienten, Einzeldosenfläschchen zu reduzierten Selbstzahlpreisen mit direkter Lieferung zu erhalten.
Zepbound ist das erste duale GLP-1/GIP-Medikament zur Behandlung von Fettleibigkeit, das von der FDA genehmigt wurde. Die Integration ergänzt die von LifeMD angebotenen apothekenbezogenen Programme mit Versicherungsschutz, bei denen die Genehmigungsraten für markenrechtlich geschützte GLP-1-Therapien steigen. Das Gewichtsmanagementprogramm des Unternehmens hat bis Februar 2025 etwa 75.000 aktive Patientenabonnenten erreicht.
Über den Selbstzahler-Apothekenkanal von LillyDirect ist Zepbound in Fläschchen mit 2,5 mg, 5 mg, 7,5 mg und 10 mg erhältlich. Lilly hat die Preise für Fläschchen mit 2,5 mg und 5 mg gesenkt und neue Optionen für Fläschchen mit 7,5 mg und 10 mg eingeführt.
- Integration with LillyDirect provides streamlined access to Zepbound at reduced prices
- Weight management program reaches 75,000 active patient subscribers
- Rising approval rates for GLP-1 therapies in insurance-sponsored programs
- Expanded product offering with additional Zepbound dose options
- None.
Insights
LifeMD's new integration with LillyDirect's pharmacy provider represents a strategic expansion of their weight management services ecosystem. By streamlining access to Lilly's Zepbound (tirzepatide) - the only FDA-approved dual GLP-1/GIP receptor agonist for obesity - LifeMD strengthens its competitive position in the telehealth weight management space.
The timing is particularly advantageous as Lilly has recently expanded Zepbound's dosing options (2.5mg, 5mg, 7.5mg, 10mg) while reducing pricing on certain vials. This alignment allows LifeMD to offer patients a more cost-effective self-pay option alongside their insurance-sponsored pharmacy programs, potentially removing a significant barrier to treatment access.
Perhaps most noteworthy is the disclosure that LifeMD's weight management program has reached approximately 75,000 active patient subscribers as of February 2025. This figure provides concrete evidence of LifeMD's traction in this therapeutic area and suggests their comprehensive approach - combining primary care, remote monitoring, diagnostics, and prescription services - is resonating with patients.
By offering direct access to branded Zepbound at reduced self-pay prices, LifeMD is addressing affordability challenges while maintaining a premium medication offering. For investors, this integration represents enhanced operational capabilities in a high-growth therapeutic category, potentially improving both patient acquisition and retention metrics as the company continues scaling its telehealth platform in the weight management sector.
NEW YORK, March 06, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, today announced it is integrating with LillyDirect pharmacy provider, Gifthealth, to offer streamlined access of single-dose vials of Lilly’s prescription obesity treatment Zepbound® (tirzepatide) to eligible LifeMD patients. Integration with the LillyDirect® self-pay pharmacy channel will provide a seamless solution to a patient’s Zepbound fulfillment journey while continuing to offer more accessible pricing and direct shipment to patients.
LifeMD’s comprehensive weight management offering provides a turnkey solution for patients seeking clinical care to lose weight and to reach their healthcare objectives. With Lilly’s recent launch of additional doses of Zepbound vials and reduced pricing of existing vial doses, the integration will provide LifeMD’s eligible on-label patients with streamlined access to this treatment, if prescribed. Zepbound is the first and only FDA-approved dual glucagon-like peptide-1 (GLP-1) receptor agonist and glucose-dependent insulinotropic polypeptide (GIP) obesity medication.
“We commend Lilly’s initiative to offer more accessible solutions for obesity treatment with the recent launch of the new Zepbound Self Pay Journey Program. Our integration with LillyDirect’s self-pay pharmacy provider further enhances LifeMD patients’ experience with seamless access to branded Zepbound vials at the newly reduced self-pay price. This new integration complements our insurance-sponsored pharmacy programs, where we continue to see rising approval rates for branded GLP-1 therapies like Zepbound,” said Justin Schreiber, Chairman and CEO of LifeMD. “LifeMD remains dedicated to elevating access to quality medical care, which starts with offering healthcare that is more patient-centric, affordable and convenient. We believe that commitment uniquely positions LifeMD’s weight management program to make healthy living accessible for our patients.”
LifeMD’s rapidly growing weight management program provides primary care, remote monitoring, diagnostic testing and prescription services to eligible patients seeking to access a medically supported weight-loss solution. The Company’s weight management program has grown to approximately 75,000 active patient subscribers as of February 2025. LifeMD remains at the forefront of the rapidly growing weight-loss market with a highly differentiated and comprehensive offering.
Zepbound is available for on-label self-pay patients in 2.5 mg, 5 mg, 7.5 mg and 10 mg dose vials through LillyDirect’s self-pay pharmacy channel. Lilly recently reduced the price of the 2.5 mg and 5 mg vials and announced the launch of the 7.5 mg and 10 mg vials.
About LifeMD, Inc.
LifeMD® is a leading provider of virtual primary care. LifeMD offers telemedicine, access to laboratory and pharmacy services, and specialized treatment across more than 200 conditions, including primary care, men’s and women’s health, weight management, and hormone therapy. The Company leverages a vertically integrated, proprietary digital care platform, a 50-state affiliated medical group, a 22,500-square-foot affiliated pharmacy, and a U.S.-based patient care center to increase access to high-quality and affordable care. For more information, please visit LifeMD.com.
Cautionary Note Regarding Forward Looking Statements
This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended; Section 21E of the Securities Exchange Act of 1934, as amended; and the safe harbor provision of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this news release may be identified by the use of words such as: “believe,” “expect,” “anticipate,” “project,” “should,” “plan,” “will,” “may,” “intend,” “estimate,” “predict,” “continue,” and “potential,” or, in each case, their negative or other variations or comparable terminology referencing future periods. Examples of forward-looking statements include, but are not limited to, statements regarding our financial outlook and guidance, short and long-term business performance and operations, future revenues and earnings, regulatory developments, legal events or outcomes, ability to comply with complex and evolving regulations, market conditions and trends, new or expanded products and offerings, growth strategies, underlying assumptions, and the effects of any of the foregoing on our future results of operations or financial condition.
Forward-looking statements are not historical facts and are not assurances of future performance. Rather, these statements are based on our current expectations, beliefs, and assumptions regarding future plans and strategies, projections, anticipated and unanticipated events and trends, the economy, and other future conditions, including the impact of any of the aforementioned on our future business. As forward-looking statements relate to the future, they are subject to inherent risk, uncertainties, and changes in circumstances and assumptions that are difficult to predict, including some of which are out of our control. Consequently, our actual results, performance, and financial condition may differ materially from those indicated in the forward-looking statements. These risks and uncertainties include, but are not limited to, “Risk Factors” identified in our filings with the Securities and Exchange Commission, including, but not limited to, our most recently filed Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and any amendments thereto. Even if our actual results, performance, or financial condition are consistent with forward-looking statements contained in such filings, they may not be indicative of our actual results, performance, or financial condition in subsequent periods.
Any forward-looking statement made in the news release is based on information currently available to us as of the date on which this release is made. We undertake no obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise, except as may be required under applicable law or regulation.
Investor Contact:
Marc Benathen, Chief Financial Officer
marc@lifemd.com
Media Contact:
Jessica Friedeman, Chief Marketing Officer
press@lifemd.com
FAQ
What is the significance of LifeMD's integration with LillyDirect for Zepbound access?
How many active subscribers does LifeMD's weight management program have in February 2025?
What Zepbound dose options are available through LifeMD's LillyDirect integration?
What makes Zepbound unique in the obesity medication market?
How does the LillyDirect integration affect LFMD's existing pharmacy programs?
